Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Cited In for PubMed (Select 14253947)

1.

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Drozda K, Müller DJ, Bishop JR.

Pharmacotherapy. 2014 Feb;34(2):166-84. doi: 10.1002/phar.1398. Review.

2.

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.

Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B.

Arch Gen Psychiatry. 2009 Sep;66(9):966-75. doi: 10.1001/archgenpsychiatry.2009.95.

3.

Pharmacogenetics of antidepressant response: an update.

Drago A, De Ronchi D, Serretti A.

Hum Genomics. 2009 Apr;3(3):257-74. Review.

4.

THE PHARMACOTHERAPY OF THE DEPRESSIVE SYNDROME.

LEHMANN HE.

Can Med Assoc J. 1965 Apr 10;92:821-8. Review.

5.

Clinical significance of plasma imipramine levels.

Walter CJ.

Proc R Soc Med. 1971 Mar;64(3):282-5. No abstract available.

6.
7.

Brain amine concentrations after monoamine oxidase inhibitor administration.

Jones AB, Pare CM, Nicholson WJ, Price K, Stacey RS.

Br Med J. 1972 Jan 1;1(5791):17-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk